BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Genmab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Genmab's drugs run\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02912949-2821@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bizengri (Zenocutuzumab): Phase 2 readout est. (NCT02912949)
DESCRIPTION:Bizengri (Zenocutuzumab)\, phase 2\, Non-Small Cell Lung Cancer
 .\nStudy: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumor
 s Harboring an NRG1 Fusion (eNRGy)\nEstimated primary completion: 31 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zenocutuzum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 2912949
URL:https://assetmemo.bio/drug/zenocutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05908734-2020@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Amivantamab: Phase 1/2 readout est. (NCT05908734)
DESCRIPTION:Amivantamab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Combination Therapy With Amivantamab and Cetrelimab in Participa
 nts With Metastatic Non-small Cell Lung Cancer\nEstimated primary completi
 on: 31 January 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 amivantamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05908734
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05451810-10986@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT05451810)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Admini
 stered in the Outpatient Setting in Adult Participants With Relapsed or Re
 fractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma\nEs
 timated primary completion: March 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05451810
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05379595-2020@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:Amivantamab: Phase 1/2 readout est. (NCT05379595)
DESCRIPTION:Amivantamab\, phase 1/2\, Colorectal Cancer.\nStudy: A Study of
  Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy 
 in Participants With Advanced or Metastatic Colorectal Cancer\nEstimated p
 rimary completion: 27 April 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/amivantamab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05379595
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05488314-2020@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:Amivantamab: Phase 1/2 readout est. (NCT05488314)
DESCRIPTION:Amivantamab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Amivantamab and Capmatinib Combination Therapy in Unresectable M
 etastatic Non-small Cell Lung Cancer\nEstimated primary completion: 28 Apr
 il 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/amivantamab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0548
 8314
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06120140-2020@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Amivantamab: Phase 2 readout est. (NCT06120140)
DESCRIPTION:Amivantamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Enh
 anced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growt
 h Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treate
 d First-line With Amivantamab Plus Lazertinib\nEstimated primary completio
 n: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/amiva
 ntamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06120140
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05578976-10986@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Epcoritamab: Phase 3 readout est. (NCT05578976)
DESCRIPTION:Epcoritamab\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcori
 tamab Combined With Intravenous and Oral Rituximab\, Cyclophosphamide\, Do
 xorubicin Hydrochloride\, Vincristine\, and Prednisone (R-CHOP) or R-CHOP 
 in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (
 DLBCL)\nEstimated primary completion: June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05578976
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05498428-2020@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20270817
DTEND;VALUE=DATE:20270818
SUMMARY:Amivantamab: Phase 2 readout est. (NCT05498428)
DESCRIPTION:Amivantamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Amivantamab in Participants With Advanced or Metastatic Solid Tumo
 rs Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cel
 l Lung Cancer\nEstimated primary completion: 17 August 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05498428
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04542824-10986@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT04542824)
DESCRIPTION:Epcoritamab\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects Wit
 h Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)\nEs
 timated primary completion: September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04542824
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604766-2708@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 3 readout est. (NCT07604766)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 3\, Ovarian Cancer.\nStud
 y: An Extension Study to Assess the Efficacy of Rina-S Compared to Treatme
 nt of Investigator's Choice in Participants With Platinum Resistant Ovaria
 n Cancer in China\nEstimated primary completion: September 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076047
 66
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04663347-10986@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT04663347)
DESCRIPTION:Epcoritamab\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B
 -cell Non-Hodgkin Lymphoma (B-NHL)\nEstimated primary completion: 30 Septe
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritama
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 663347
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05201248-10986@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT05201248)
DESCRIPTION:Epcoritamab\, phase 1/2.\nStudy: A Study to Evaluate Adverse Ev
 ents and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Mo
 notherapy or Combined With Standard of Care Therapies in Adult Participant
 s in China With B-Cell Non-Hodgkin Lymphoma\nEstimated primary completion:
  October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcori
 tamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05201248
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288177-2708@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20271122
DTEND;VALUE=DATE:20271123
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 2 readout est. (NCT07288177)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 2\, Non-Small Cell Lung C
 ancer.\nStudy: Study to Assess the Efficacy and Safety of Rina-S in Partic
 ipants With Non-small Cell Lung Cancer\nEstimated primary completion: 22 N
 ovember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rinatab
 art-sesutecan-rina-s#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07288177
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04623541-10986@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT04623541)
DESCRIPTION:Epcoritamab\, phase 1/2.\nStudy: Safety and Efficacy Study of E
 pcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukem
 ia and Richter's Syndrome\nEstimated primary completion: December 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04623541
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06750094-2020@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Amivantamab: Phase 3 readout est. (NCT06750094)
DESCRIPTION:Amivantamab\, phase 3\, Colorectal Cancer.\nStudy: A Study of A
 mivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Partici
 pants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previou
 sly Received Chemotherapy\nEstimated primary completion: 15 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06750094
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06508658-10986@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Epcoritamab: Phase 3 readout est. (NCT06508658)
DESCRIPTION:Epcoritamab\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tabl
 ets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemci
 tabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or R
 efractory Diffuse Large B-Cell Lymphoma\nEstimated primary completion: Mar
 ch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0650
 8658
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07586202-2020@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20280302
DTEND;VALUE=DATE:20280303
SUMMARY:Amivantamab: Phase 2 readout est. (NCT07586202)
DESCRIPTION:Amivantamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in 
 Participants With Resectable EGFR-Mutated NSCLC\nEstimated primary complet
 ion: 2 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/am
 ivantamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07586202
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06885840-2050@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Pamvatamig: Phase 2 readout est. (NCT06885840)
DESCRIPTION:Pamvatamig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Stud
 y of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with
  AGA and MET Amplification.\nEstimated primary completion: April 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pamvatamig#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06885840
URL:https://assetmemo.bio/drug/pamvatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04930432-2050@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Pamvatamig: Phase 1/2 readout est. (NCT04930432)
DESCRIPTION:Pamvatamig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: St
 udy of MCLA-129\, a Human Bispecific EGFR and cMet Antibody\, in Patients 
 With Advanced NSCLC and Other Solid Tumors\nEstimated primary completion: 
 30 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pamvat
 amig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04930432
URL:https://assetmemo.bio/drug/pamvatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07539311-2708@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 2 readout est. (NCT07539311)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 2.\nStudy: Study to Asses
 s the Efficacy and Safety of Rina-S in Participants With Advanced Gastroin
 testinal (GI) Cancers\nEstimated primary completion: September 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/rinatabart-sesutecan-rina-
 s#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 539311
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225270-2708@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 3 readout est. (NCT07225270)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 3\, Ovarian Cancer.\nStud
 y: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care
  Compared to Standard of Care for Maintenance Treatment of Participants Wi
 th Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Plat
 inum-based Doublet Chemotherapy\nEstimated primary completion: October 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/rinatabart-sesutec
 an-rina-s#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07225270
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227025-2020@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Amivantamab: Phase 1/2 readout est. (NCT07227025)
DESCRIPTION:Amivantamab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Amivantamab and Olomorasib Combination Therapy in Participants W
 ith Metastatic Non-Small Cell Lung Cancer\nEstimated primary completion: 3
 0 November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/amiv
 antamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07227025
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05579366-2708@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 1/2 readout est. (NCT05579366)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 1/2\, Non-Small Cell Lung
  Cancer.\nStudy: Rinatabart Sesutecan (Rina-S\, PRO1184\, GEN1184) for Adv
 anced Solid Tumors (GCT1184-01/ PRO1184-001)\nEstimated primary completion
 : December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rina
 tabart-sesutecan-rina-s#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05579366
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06662786-2020@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Amivantamab: Phase 3 readout est. (NCT06662786)
DESCRIPTION:Amivantamab\, phase 3\, Colorectal Cancer.\nStudy: A Study of A
 mivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIR
 I as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-typ
 e Unresectable or Metastatic Left-sided Colorectal Cancer\nEstimated prima
 ry completion: 15 December 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/amivantamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06662786
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03625037-10986@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT03625037)
DESCRIPTION:Epcoritamab\, phase 1/2\, Large B-Cell Lymphoma.\nStudy: First-
 in-Human (FIH) Trial in Patients With Relapsed\, Progressive or Refractory
  B-Cell Lymphoma\nEstimated primary completion: January 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT03625037
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07448116-2050@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Pamvatamig: Phase 1/2 readout est. (NCT07448116)
DESCRIPTION:Pamvatamig\, phase 1/2.\nStudy: Study of MCLA-129 in Combinatio
 n With Ensartinib in Patients With Advanced Solid Tumors.\nEstimated prima
 ry completion: 1 February 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pamvatamig#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07448116
URL:https://assetmemo.bio/drug/pamvatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06667076-2020@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20290523
DTEND;VALUE=DATE:20290524
SUMMARY:Amivantamab: Phase 2 readout est. (NCT06667076)
DESCRIPTION:Amivantamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Amivantamab in Combination With Lazertinib\, or Amivantamab in Com
 bination With Platinum-Based Chemotherapy\, for Common Epidermal Growth Fa
 ctor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell
  Lung Cancer (NSCLC)\nEstimated primary completion: 23 May 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06667076
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07276399-2020@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20290618
DTEND;VALUE=DATE:20290619
SUMMARY:Amivantamab: Phase 3 readout est. (NCT07276399)
DESCRIPTION:Amivantamab\, phase 3\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: A Study of Amivantamab in Addition to Standard of Care Agents (SOC
 ) Compared With SOC Alone in Participants With Recurrent/Metastatic Head a
 nd Neck Cancer\nEstimated primary completion: 18 June 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07276399
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07166094-2708@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 3 readout est. (NCT07166094)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 3\, Endometrial Cancer.\n
 Study: Study to Assess the Efficacy and Safety of Rina-S Compared to Treat
 ment of Investigator's Choice in Participants With Endometrial Cancer\nEst
 imated primary completion: August 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07166094
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05409066-10986@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Epcoritamab: Phase 3 readout est. (NCT05409066)
DESCRIPTION:Epcoritamab\, phase 3\, Follicular Lymphoma.\nStudy: Study of S
 ubcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral
  Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity
  in Adult Participants With Follicular Lymphoma\nEstimated primary complet
 ion: December 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 pcoritamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05409066
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07564141-2708@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 3 readout est. (NCT07564141)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 3\, Ovarian Cancer.\nStud
 y: Study to Assess the Efficacy and Safety of Rina-S With or Without Bevac
 izumab Compared to Investigator's Choice of Platinum-based Chemotherapy Wi
 th or Without Bevacizumab as Second-line Treatment in Participants With Re
 current Platinum-sensitive Ovarian Cancer\nEstimated primary completion: D
 ecember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rinatab
 art-sesutecan-rina-s#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07564141
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07859215-2708@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 3 readout est. (NCT07859215)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 3\, Ovarian Cancer.\nStud
 y: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care
  Compared to Standard of Care Maintenance Treatment After First-line (1L) 
 Platinum-based Chemotherapy in Participants With Ovarian Cancer\nEstimated
  primary completion: March 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07859215
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05283720-10986@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT05283720)
DESCRIPTION:Epcoritamab\, phase 2.\nStudy: A Study to Evaluate Adverse Even
 ts and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Comb
 ination With Oral and Intravenous Anti-Neoplastic Agents in Adult Particip
 ants With Non-Hodgkin Lymphoma\nEstimated primary completion: November 203
 2. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05283720
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06385080-2020@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20321227
DTEND;VALUE=DATE:20321228
SUMMARY:Amivantamab: Phase 1/2 readout est. (NCT06385080)
DESCRIPTION:Amivantamab\, phase 1/2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: A Study of Amivantamab Alone or in Addition to Other Treatment A
 gents in Participants With Head and Neck Cancer\nEstimated primary complet
 ion: 27 December 2032. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/amivantamab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06385080
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06191744-10986@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20371130
DTEND;VALUE=DATE:20371201
SUMMARY:Epcoritamab: Phase 3 readout est. (NCT06191744)
DESCRIPTION:Epcoritamab\, phase 3\, Follicular Lymphoma.\nStudy: Study of S
 ubcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral
  Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity
  in Adult Participants With Previously Untreated Follicular Lymphoma\nEsti
 mated primary completion: November 2037. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06191744
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
